+

WO2006025029A3 - Composition de divalproex a liberation prolongee - Google Patents

Composition de divalproex a liberation prolongee Download PDF

Info

Publication number
WO2006025029A3
WO2006025029A3 PCT/IB2005/052857 IB2005052857W WO2006025029A3 WO 2006025029 A3 WO2006025029 A3 WO 2006025029A3 IB 2005052857 W IB2005052857 W IB 2005052857W WO 2006025029 A3 WO2006025029 A3 WO 2006025029A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
divalproex
release composition
lactose
pharmaceutical composition
Prior art date
Application number
PCT/IB2005/052857
Other languages
English (en)
Other versions
WO2006025029A2 (fr
Inventor
Pratik Kumar
Girish Kumar Jain
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Pratik Kumar
Girish Kumar Jain
Ashok Rampal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Pratik Kumar, Girish Kumar Jain, Ashok Rampal filed Critical Ranbaxy Lab Ltd
Publication of WO2006025029A2 publication Critical patent/WO2006025029A2/fr
Publication of WO2006025029A3 publication Critical patent/WO2006025029A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une composition pharmaceutique à libération prolongée, qui comprend du sodium de divalproex et du lactose, la quantité de lactose étant inférieure à 8% en poids du poids total de la composition pharmaceutique.
PCT/IB2005/052857 2004-08-31 2005-08-31 Composition de divalproex a liberation prolongee WO2006025029A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1649DE2004 2004-08-31
IN1649/DEL/2004 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006025029A2 WO2006025029A2 (fr) 2006-03-09
WO2006025029A3 true WO2006025029A3 (fr) 2006-05-18

Family

ID=35636703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/052857 WO2006025029A2 (fr) 2004-08-31 2005-08-31 Composition de divalproex a liberation prolongee

Country Status (1)

Country Link
WO (1) WO2006025029A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (fr) * 1998-12-18 2000-06-29 Abbott Laboratories Preparation a liberation controlee de divalproex sodium
WO2002051401A2 (fr) * 2000-12-22 2002-07-04 Abbott Laboratories Formulation a liberation controlee de sodium de divalproex
WO2002051402A1 (fr) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee
WO2004071424A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Preparation de n-(2-propylpentanoyl)glycinamide a liberation immediate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037055A1 (fr) * 1998-12-18 2000-06-29 Abbott Laboratories Preparation a liberation controlee de divalproex sodium
WO2002051401A2 (fr) * 2000-12-22 2002-07-04 Abbott Laboratories Formulation a liberation controlee de sodium de divalproex
WO2002051402A1 (fr) * 2000-12-22 2002-07-04 Abbott Laboratories Controlled release formulation of divalproex sodium
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee
WO2004071424A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Preparation de n-(2-propylpentanoyl)glycinamide a liberation immediate

Also Published As

Publication number Publication date
WO2006025029A2 (fr) 2006-03-09

Similar Documents

Publication Publication Date Title
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
EP1834637A4 (fr) Preparation prophylactique/therapeutique contre une maladie due aux radicaux libres
WO2005089729A3 (fr) Formulations galeniques de composes organiques
CA2469369A1 (fr) Compositions contenant des antihistaminiques sedatifs et des antihistaminiques non sedatifs
WO2004078712A3 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
WO2007011619A3 (fr) Formes pharmaceutiques orales hautement biodisponibles a liberation retardee, de o-desmethylvenlafaxine succinate
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO2007146248A3 (fr) Préparations de laquinimod stables
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
HK1151787A1 (en) Calcium hypochlorite compositions and methods for decreasing the tendency of calcium hypochlorite formulations to undergo conflagration
IL188758A (en) Tetrahydrobenzazepines are stored in aryl and heteroaryl, containing pharmaceutical preparations and methods for preparing them
WO2006119283A3 (fr) Compositions anti-odeurs et utilisation therapeutique associee
WO2008006514A8 (fr) Combinaisons de principes actifs ayant des propriétés insecticides et acaricides
WO2006024479A3 (fr) Compositions pharmaceutiques
WO2004047792A3 (fr) Glucocorticoides liposomaux
SE0501556L (sv) Förstärkt absorption
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
AU2003297840A1 (en) Chemopreventive and therapeutic aspects of polyphenolic compositions and assays
WO2006087629A3 (fr) Composition de medicament antipsychotique a delitement rapide
AU2002256304A1 (en) Compositions for delivery of compounds to cells and methods of use
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2007002897A3 (fr) Compositions destinees a ameliorer la biodisponibilite de polymethoxyflavones et de tocotrienols pour le traitement d'une maladie cardiovasculaire
TW200600098A (en) Solid orally ingestible formulations of tetrodotoxin
HUP0401633A3 (en) Use of irbesartan for the preparation of pharmaceutical compositions that are used to prevent or treat pulmonary hypertension
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1637/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载